How do we follow-up PAH patients non-responsive to therapy and how can therapy be optimized?

How do we followup PAH patients nonresponsive to therapy and how can therapy be optimized
3' education - Jan. 10, 2017 - Bologna, Italy - Nazzareno Galiè, MD - Online CME
  • Overview

    In this 8th video of a pulmonary arterial hypertension series, prof. dr. Galiè mentions further treatment options for non-responsive patients, including transplantation, and the organization of referral centers for most optimal care of patients.

  • Educational information

    This educational series of videos aims to provide more insights into the pathophysiology and management of pulmonary arterial hypertension (PAH). By addressing some of the key questions viewers will receive a compact update on current understanding and guidelines of PAH

    • Q1: What is the underlying pathophysiology of PAH and what are its characteristics?
    • Q2: Which clinical pulmonary hypertension (PH) groups can be distinguished?
    • Q3: How common is PAH and what are its risk factors?
    • Q4: How is PAH diagnosed?
    • Q5: How can PH patients be functionally classified?
    • Q6: How is the prognosis of PAH established?
    • Q7: Which treatment options can be pursued and which drugs are approved for PAH?
    • Q8: How do we follow-up PAH patients non-responsive to therapy and how can therapy be optimized?
  • Disclosures

    Prof Nazzareno Galiè , Institute of Cardiology, University of Bologna, Bologna, Italy

    Nazzareno Galiè, MD, heads the Pulmonary Hypertension Centre at the Institute of Cardiology and is Associate Professor of Cardiology at the Medical Faculty of the University of Bologna, Italy. He also teaches at the Postgraduate Medical Schools of Cardiology, Pulmonary Diseases, and Rheumatology at the University of Bologna. He is Director of the International Master Degree in Pulmonary Vascular Diseases of the University of Bologna

    He is past-Chairman of the working group on pulmonary circulation of the European Society of Cardiology and of the joint task force of the European Society of Cardiology and the European Respiratory Society for the guidelines on pulmonary hypertension

  • Disclosures

    This educational video series is funded via an unrestricted educational grant provided by Pfizer

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free